Improved Outcome in Renal Transplant Recipients Treated With Simulect Versus Okt3 Induction.

Pelletier, Ronald P.; Davies, Elizabeth; Elkhammas, Elmahdi A; Bumgardner, Ginny L.; Henry, M.; Ferguson, Ronald M.

doi:10.1097/00007890-200004271-00170

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Equine antithymocyte globulin (ATG) is uncommonly used nowadays, and the single study in which basiliximab was compared with this drug (Sollinger et al 2001) will not be discussed further, other than to note that the incidence of biopsy-proven rejection was similar between the two groups. Comparing muromonab CD3 and basiliximab, one large study with 271 patients (Pelletier et al 2000) found no differences in acute rejection between treatment groups, but three other studies with a total of 368 patients (Chowdhury et al 2001;Kumar et al 2001;Kode et al 2003) reported that basiliximab was associated with lower incidences of acute rejection than muromonab CD3 and fewer adverse advents. Five-year follow-up is available from one single-center study (Shoskes et al 2006) in which 52 recipients were randomized to receive OKT3 or basiliximab; the incidence of acute rejection was similar between the two groups during the fi ve-year period.…”

Section: Basiliximab Vs Other Inducing Agentsmentioning

confidence: 99%

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Salis

Caccamo

Verzaro

et al. 2008

BTT

View full text Add to dashboard Cite

Basiliximab is a chimeric mouse-human monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor on activated T lymphocytes. It was shown in phase III trials to reduce the number and severity of acute rejection episodes in the fi rst year following renal transplantation in adults and children, with a reasonable cost-benefi t ratio. The drug does not increase the incidence of opportunistic infections or malignancies above baseline in patients treated with conventional calcineurin inhibitor-based immunosuppression. In the fi eld of renal transplantation, basiliximab does not increase kidney or patient survival, despite the reduction in the number of rejection episodes. Basiliximab may reduce the incidence of delayed graft function. In comparison with lymphocyte-depleting antibodies basiliximab appears to have equal effi cacy in standard immunological risk patients. Recently, IL-2 receptor monoclonal antibodies have been used with the objective of reducing or eliminating the more toxic elements of the standard immunosuppression protocol. Several trials have incorporated basiliximab in protocols designed to avoid or withdraw rapidly corticosteroids, as well as protocols which substitute target-of-rapamycin (TOR) inhibitors for calcineurin inhibitors.

show abstract

Section: Basiliximab Vs Other Inducing Agentsmentioning

confidence: 99%

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Salis

Caccamo

Verzaro

et al. 2008

BTT

View full text Add to dashboard Cite

show abstract

Nuevos tratamientos inmunodepresores de inducción en el trasplante renal

Pascual

Ortuño

2001

Medicina Clínica

View full text Add to dashboard Cite

Basiliximab

Chapman¹,

Keating²

2003

Drugs

132

View full text Add to dashboard Cite

Basiliximab reduces acute rejection without increasing the incidence of adverse events, including infection and malignancy, in renal transplant recipients when combined with standard dual- or triple-immunotherapy. The overall incidence of death, graft loss or acute rejection was significantly reduced at 3 years; there was no significant difference for this endpoint 5 years after transplantation. Malignancy was not increased at 5 years. The overall efficacy, tolerability, ease of administration and cost effectiveness of basiliximab make it an attractive option for the prophylaxis of acute renal transplant rejection.

show abstract

Improved Outcome in Renal Transplant Recipients Treated With Simulect Versus Okt3 Induction.

Cited by 3 publications

References 0 publications

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Nuevos tratamientos inmunodepresores de inducción en el trasplante renal

Basiliximab

Contact Info

Product

Resources

About